Antiplatelet Agent-Related Peptic Ulcer Disease.
- Author:
Young Woon CHANG
1
Author Information
1. Department of Gastroenterology, Kyung Hee University College of Medicine, Seoul, Korea. cywgi@chollian.net
- Publication Type:Review
- Keywords:
Antiplatelet-related peptic ulcer;
Proton pump inhibitor
- MeSH:
Aspirin;
Cardiovascular Diseases;
Eating;
Helicobacter pylori;
Humans;
Peptic Ulcer*;
Platelet Aggregation Inhibitors;
Proton Pumps;
Risk Factors;
Smoke;
Smoking;
Ulcer
- From:Korean Journal of Medicine
2014;86(6):673-677
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Antiplatelet therapies have been widely used to prevent cardiovascular diseases. However, antiplatelet agents cause gastrointestinal (GI) damage and are associated with a greater risk of gastroduodenal ulcers and life-threatening ulcer complications. The first step to reduce the GI risk of antiplatelet therapy is to assess whether the patient requires continuous antiplatelet therapy. The second step is to eliminate risk factors that may place the patient at greater GI risk such as Helicobacter pylori infection, NSAID use, steroid ingestion, and smoking. Continuous aspirin therapy plus a powerful proton pump inhibitor (PPI) is the choice of treatment for antiplatelet-related peptic ulcers. The risk of cardiovascular complications and risk of gastric complication using antiplatelet agents should be evaluated individually.
